Article Search

Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer

July 1, 2026

Is this the end of the cisplatin era in bladder cancer? It sure seems that way. The results here are no surprise based on the signal we saw in the metastatic setting.

Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy

July 1, 2026

It comes as no surprise that bispecific agents are moving up into earlier lines of therapy in multiple myeloma. Here, in the setting of early relapsed, anti-CD38 and –imid exposed patients, single agent teclistimab showed an 18mo progression-free survival benefit over PFd/Kd.

Keyword Search

Article Archive (2021)

Article Search

Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer

Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy

Keyword Search

Article Search

Cancer Types

Month Contributed

Show FCS Articles Only

Sort Order

Number of Posts

Menu

About This Site